148 related articles for article (PubMed ID: 19621240)
1. Overexpression of PTK6 (breast tumor kinase) protein--a prognostic factor for long-term breast cancer survival--is not due to gene amplification.
Aubele M; Vidojkovic S; Braselmann H; Ritterswürden D; Auer G; Atkinson MJ; Tapio S; Höfler H; Rauser S; Bartlett JM
Virchows Arch; 2009 Aug; 455(2):117-23. PubMed ID: 19621240
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients.
Aubele M; Walch AK; Ludyga N; Braselmann H; Atkinson MJ; Luber B; Auer G; Tapio S; Cooke T; Bartlett JM
Br J Cancer; 2008 Oct; 99(7):1089-95. PubMed ID: 18781181
[TBL] [Abstract][Full Text] [Related]
3. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
4. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas.
Aubele M; Auer G; Walch AK; Munro A; Atkinson MJ; Braselmann H; Fornander T; Bartlett JM
Br J Cancer; 2007 Mar; 96(5):801-7. PubMed ID: 17299391
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification.
Orsaria M; Khelifa S; Buza N; Kamath A; Hui P
J Clin Pathol; 2013 Dec; 66(12):1070-5. PubMed ID: 23908451
[TBL] [Abstract][Full Text] [Related]
6. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous over-expression of the Her2/neu and PTK6 tyrosine kinases in archival invasive ductal breast carcinomas.
Born M; Quintanilla-Fend L; Braselmann H; Reich U; Richter M; Hutzler P; Aubele M
J Pathol; 2005 Apr; 205(5):592-6. PubMed ID: 15685689
[TBL] [Abstract][Full Text] [Related]
8. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
9. The expression and prognostic value of protein tyrosine kinase 6 in early-stage cervical squamous cell cancer.
Wang XJ; Xiong Y; Ma ZB; Xia JC; Li YF
Chin J Cancer; 2016 Jun; 35(1):54. PubMed ID: 27311570
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
[TBL] [Abstract][Full Text] [Related]
11. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy.
Bose S; Mohammed M; Shintaku P; Rao PN
Breast J; 2001; 7(5):337-44. PubMed ID: 11906444
[TBL] [Abstract][Full Text] [Related]
12. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
13. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
[TBL] [Abstract][Full Text] [Related]
14. Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.
Qiu L; Levine K; Gajiwala KS; Cronin CN; Nagata A; Johnson E; Kraus M; Tatlock J; Kania R; Foley T; Sun S
PLoS One; 2018; 13(6):e0198374. PubMed ID: 29879184
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic significance of chromosome 17 polysomy in breast cancer].
Lü YL; Zhong M; Liu L; Wei LX; Zhao P
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):88-91. PubMed ID: 18681318
[TBL] [Abstract][Full Text] [Related]
16. Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials.
Batistatou A; Kotoula V; Bobos M; Kouvatseas G; Zagouri F; Tsolaki E; Gogas H; Koutras A; Pentheroudakis G; Timotheadou E; Pervana S; Goussia A; Petraki K; Sotiropoulou M; Koletsa T; Razis E; Kosmidis P; Aravantinos G; Papadimitriou C; Pectasides D; Fountzilas G
Clin Breast Cancer; 2018 Feb; 18(1):53-62.e3. PubMed ID: 28870680
[TBL] [Abstract][Full Text] [Related]
17. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications.
Tanner MM; Tirkkonen M; Kallioniemi A; Holli K; Collins C; Kowbel D; Gray JW; Kallioniemi OP; Isola J
Clin Cancer Res; 1995 Dec; 1(12):1455-61. PubMed ID: 9815944
[TBL] [Abstract][Full Text] [Related]
18. Targeting protein tyrosine kinase 6 in cancer.
Gilic MB; Tyner AL
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188432. PubMed ID: 32956764
[TBL] [Abstract][Full Text] [Related]
19. Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer.
Ludyga N; Anastasov N; Gonzalez-Vasconcellos I; Ram M; Höfler H; Aubele M
Mol Biosyst; 2011 May; 7(5):1603-12. PubMed ID: 21380407
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of primed in situ labelling in determination of HER-2 gene amplification and CEN-17 status in breast cancer tissue.
Salimi M; Mozdarani H; Majidzadeh-A K
Asian Pac J Cancer Prev; 2012; 13(1):329-37. PubMed ID: 22502695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
